Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors
AssigneePfizer Inc.
InventorsDavid A. Fryburg, Earl Michael Gibbs
Life of this patent
Estimating the term…
Abstract
This invention is directed to a method of treating insulin resistance syndrome (IRS), hypertension and/or type 2 diabetes in a mammal comprising administering to said mammal a cGMP PDE9 inhibitor or a pharmaceutical composition thereof. This invention is also directed to such methods wherein said cGMP PDE9 inhibitor is used in combination with other agents to treat IRS, hypertension and/or type 2 diabetes.
Claims32
A method of treating insulin resistance syndrome in a mammal comprising administering to said mammal a cGMP PDE9 inhibitor, a prodrug or solvate thereof or a pharmaceutically acceptable salt of said PDE9 inhibitor, prodrug, solvate or salt.
A method of treating type 2 diabetes in a mammal comprising administering to said mammal a cGMP PDE9 inhibitor, a prodrug or solvate thereof or a pharmaceutically acceptable salt of said PDE9 inhibitor, prodrug, solvate or salt.
A method of treating dyslipidemia in a mammal comprising administering to said mammal a cGMP PDE9 inhibitor, a prodrug or solvate thereof or a pharmaceutically acceptable salt of said PDE9 inhibitor, prodrug, solvate or salt.
A method of treating impaired glucose tolerance in a mammal comprising administering to said mammal a CGMP PDE9 inhibitor, a prodrug or solvate thereof or a pharmaceutically acceptable salt of said PDE9 inhibitor, prodrug, solvate or salt.
A method of treating polycystic ovary syndrome in a mammal comprising administering to said mammal a cGMP PDE9 inhibitor, a prodrug or solvate thereof or a pharmaceutically acceptable salt of said PDE9 inhibitor, prodrug, solvate or salt.
A combination comprising a cGMP PDE9 inhibitor and one or more of a protein kinase inhibitor;
- an AMP-activated protein kinase;
- a weight loss agent;
- insulin;
- a PPAR-γ agonist;
- a PPAR-γ antagonist;
- a PPAR-α agonist;
- a dual PPAR-γ/PPAR-α agonist;
- a sorbitol dehydrogenase inhibitor;
- a glycogen phosphorylase inhibitor;
- a biguamide;
- an HMG-CoA reductase inhibitor;
- an aldose reductase inhibitor;
- or a PDE5 inhibitor.
A kit comprising:
- a) a first unit dosage form comprising a cGMP PDE9 inhibitor, a prodrug or solvate thereof or a pharmaceutically acceptable salt of said compound, prodrug or solvate and a pharmaceutically acceptable carrier, vehicle or diluent;
- b) a second unit dosage form comprising:
- a protein kinase inhibitor;
- an AMP-activated protein kinase;
- a weight loss agent;
- insulin;
- a PPAR-γ agonist;
- a PPAR-γ antagonist;
- a PPAR-α agonist;
- a dual PPAR-γ/PPAR-α agonist;
- a sorbitol dehydrogenase inhibitor;
- a glycogen phosphorylase inhibitor;
- a biguamide;
- an HMG-CoA reductase inhibitor;
- an aldose reductase inhibitor;
- or
- a PDE5 inhibitor;
- a prodrug or solvate of said protein kinase inhibitor, AMP-activated protein, weight loss agent, insulin, PPAR-γ agonist, PPAR-γ antagonist, PPAR-α agonist, dual PPAR-γ/PPAR-α agonist, sorbitol dehydrogenase inhibitor, glycogen phosphorylase inhibitor, biguamide, vastatin, aldose reductase inhibitor or PDE5 inhibitor;
- or a pharmaceutically acceptable salt thereof or of said prodrug or solvate and a pharmaceutically acceptable carrier, vehicle or diluent;
- and
- c) a container.
A kit comprising:
- a) a first unit dosage form comprising a cGMP PDE9 inhibitor, a prodrug or solvate thereof or a pharmaceutically acceptable salt of said compound, prodrug or solvate and a pharmaceutically acceptable carrier, vehicle or diluent;
- b) a second unit dosage form comprising a cGMP PDE5 inhibitor, a prodrug or solvate thereof or a pharmaceutically acceptable salt of said compound, prodrug or solvate and a pharmaceutically acceptable carrier, vehicle or diluent;
- c) a third unit dosage form comprising a cGMP PDE11 inhibitor, a prodrug or solvate thereof or a pharmaceutically acceptable salt of said compound, prodrug or solvate and a pharmaceutically acceptable carrier, vehicle or diluent;
- and
- d) a container.
A method of treating type 2 diabetes in a mammal comprising administering to said mammal a compound that increases intracellular cGMP in said mammal.
A method of treating insulin resistance syndrome in a mammal comprising administering to said mammal a compound that increases intracellular cGMP in said mammal.
A method of treating polycystic ovary syndrome in a mammal comprising administering to said mammal a compound that increases intracellular cGMP in said mammal.
A method of treating dyslipidemia in a mammal comprising administering to said mammal a compound that increases intracellular cGMP in said mammal.
A method of treating impaired glucose tolerance in a mammal comprising administering to said mammal a compound that increases intracellular cGMP in said mammal.
Dependencies are inferred from the claim text.